Tyra Biosciences price target raised to $36 from $30 at Oppenheimer

Oppenheimer analyst Matthew Biegler raised the firm’s price target on Tyra Biosciences (TYRA) to $36 from $30 and keeps an Outperform rating on the shares after hosting the company for meetings in Boston on Monday. In each meeting, management made the case for why dabogratinib’s combined market opportunity exceeds $10B. That’s nearly Regeneron-esque revenues. Despite that, investors still complain that all the major catalysts aren’t until 2026. Nonetheless, the firm tells investors, “don’t expect to find shares at this price – with a sub-$500M enterprise value – next year.”